• Reuters

    Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up

    Detailed data on Monday from the 157-patient trial showed that after two and a half years, melanoma patients that had received the cancer vaccine combination showed an overall survival rate of 96%, compared with 90.2% with Keytruda alone. About 75% of the patients on the vaccine combination had recurrence-free survival, compared with 55.6% on Keytruda alone.

  • The Canadian Press

    President Joe Biden's son Hunter arrives for jury selection in a federal gun case

    WILMINGTON, Del. (AP) — President Joe Biden's son Hunter arrived at court Monday for jury selection in a federal gun case against after the collapse of a deal with prosecutors that would have avoided the spectacle of a trial so close to the 2024 election. Hunter Biden, who spent the weekend with his father has been charged in Delaware with three felonies stemming from a 2018 firearm purchase when he was, according to his memoir, in the throes of a crack addiction. He has been accused of lying to

  • Investor's Business Daily

    Dow Jones Futures: Nvidia, AMD Rise As CEOs Tout AI Chip Roadmaps

    Futures loom after the stock market showed resilience Friday. Nvidia CEO Huang made a big AI speech Sunday. Tesla EV rivals stepped up sales.